Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes-Reference-Cited by-全球学者库

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes

Published:2017-02-27 Issue:7 Volume:83 Page:1556-1570
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Ou Huang-Tz¹²,Chang Kai-Cheng³,Li Chung-Yi⁴⁵,Wu Jin-Shang⁶⁷

Affiliation:

1. Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; National Cheng Kung University; Tainan Taiwan

2. Department of Pharmacy, College of Medicine; National Cheng Kung University; Tainan Taiwan

3. Department of Pharmacy; Chang Gung Memorial Hospital-Linkou; Tao-Yuan Taiwan

4. Taiwan Department of Public Health, College of Medicine; National Cheng Kung University; Tainan Taiwan

5. Department of Public Health; China Medical University; Taichung Taiwan

6. Department of Family Medicine, College of Medicine; National Cheng Kung University; Tainan Taiwan

7. Department of Family Medicine; National Cheng Kung University Hospital; Tainan Taiwan

Funder

Ministry of Science and Technology, Taiwan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13241/fullpdf

Reference50 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res 2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes;Alexander;Br J Pharmacol,2015

3. World Health Organization Diabetes Fact Sheet http://www.who.int/mediacentre/factsheets/fs312/en/

4. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD;Rydén;Eur Heart J,2013

5. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993;Gu;Diabetes Care,1998

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis;eClinicalMedicine;2023-03

2. Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM;Diabetes and Cardiovascular Disease;2023

3. DPP4 as a Potential Candidate in Cardiovascular Disease;Journal of Inflammation Research;2022-09

4. Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies;Scientific Reports;2022-01-07

5. Retinol-Binding Protein-4—A Predictor of Insulin Resistance and the Severity of Coronary Artery Disease in Type 2 Diabetes Patients with Coronary Artery Disease;Biology;2021-09-01